Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 7, 2007 Brian Orelli	Financing Your Acquisition Schering-Plough is one step closer to financing its $14 billion acquisition of the Organon BioSciences unit of Akzo Nobel, by making an official stock offering.
The Motley Fool October 23, 2007 Brian Orelli	Schering Ploughed Down Investors punish the pharmaceutical company when it misses Wall Street expectations following 11 consecutive quarters of double-digit sales growth.
The Motley Fool April 24, 2008 Brian Orelli	Is Schering-Plough the Comeback Kid? Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs.
The Motley Fool June 11, 2007 Brian Lawler	Overseas Action for SGP Schering gets an expanded label and begins marketing another drug overseas. Investors often overlook the importance that markets outside the U.S. offer for pharmaceutical products.
The Motley Fool July 21, 2009 Brian Orelli	Merck and Schering: A Less Ugly Bride and Groom Merck and Schering-Plough are up today on "better than expected" earnings, but the bride and groom don't look all that great heading into the wedding.
The Motley Fool February 13, 2008 Brian Orelli	Schering-Plough Has No Love for the Media Apart from the press bashing regarding the company's cholesterol-lowering drug Enhance, Schering reported a pretty nice quarter.
The Motley Fool April 4, 2008 Brian Orelli	Why Is Schering Cutting Now? The latest pharmaceutical company to jump on the cost-cutting bandwagon is Schering-Plough.
The Motley Fool April 21, 2009 Brian Orelli	Schering and Merck: A Match Made in Purgatory Until Merck can show that it's capable of growing sales again, investors should be leery of stepping in, even with the dividend yield pushing 6%.
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
The Motley Fool February 4, 2009 Brian Orelli	The Tale of 2 Drugmakers Merck and Schering-Plough typically release earnings on the same day because they share sales of cholesterol drugs Vytorin and Zetia, but the drugmakers are far from the same.
The Motley Fool February 14, 2008 Brian Orelli	A Lovey-Dovey Duo Drug companies Schering-Plough and Merck hook up to market a 'hot, hot, hot!' product.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool July 22, 2008 Brian Orelli	Drug Duo SEAS Disappointment -- Again After numerous disappointments this year, Merck and Schering-Plough continue their string of bad luck.
The Motley Fool October 21, 2008 Brian Orelli	Schering Buys Great Growth Acquiring Organon Biosciences saves the company from a rough quarter.
The Motley Fool January 30, 2007 Brian Lawler	Schering-Plough Pushes Ahead The drugmaker successfully continues with its multi-year turnaround plan. Investors would be smart to take a look at this pharmaceutical turnaround stock before it starts to get noticed again.
The Motley Fool January 15, 2008 Brian Orelli	No Enhance-ment From Zetia Merck and Schering report bad news, but how much will it affect sales? Investors, take note.
The Motley Fool January 25, 2005 Stephen D. Simpson	Schering-Plough Turning a Corner The troubled pharmaceutical company begins to show signs of life. Investors looking for a more stable play would do well to look at other shares instead.
The Motley Fool November 25, 2008 Brian Orelli	Schering's Peacock Imitation The company lays out its pipeline for investors to see; there are some potential blockbusters waiting there.
The Motley Fool March 31, 2008 Brian Orelli	No Blood-Pumping Love for Merck and Schering From the reports coming out of the American College of Cardiology meeting, it looks like the drugmakers Merck and Schering-Plough took a beating.
The Motley Fool August 28, 2008 Brian Orelli	Schering and Pfizer Aren't Horsing Around Schering sells some animal health products to Pfizer to keep the EU happy.
The Motley Fool March 2, 2010 Brian Orelli	Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off.
The Motley Fool February 16, 2010 Brian Orelli	Merck Gets a Pass, for Now Its first quarter looks promising, but not as good as could be hoped.
The Motley Fool June 30, 2008 Brian Orelli	Merck and Schering Get Half a Divorce The lovey-dovey duo ends their respiratory partnership.
The Motley Fool October 23, 2006 Brian Lawler	The New Schering-Plough Possibly the cheapest large-cap pharmaceutical company compared with its growth potential, the new Schering-Plough is no dirt. Investors craving only one domestic large-cap pharma stock might be happiest with the new Schering.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool November 4, 2009 Brian Orelli	An Ode to Schering-Plough Mergers and acquisitions in the pharmaceutical industry are cataloged in a poem.
The Motley Fool May 21, 2009 Brian Orelli	Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose.
The Motley Fool December 26, 2007 Brian Orelli	Inflamed Anti-Inflammatory Contract Revised J&J and Schering revise their agreement over anti-TNF compounds.
The Motley Fool August 14, 2009 Brian Orelli	The Schizophrenic Drug Approval Schering's drug gets a thumbs-up.
BusinessWeek October 2, 2006 Gene G. Marcial	Shopping For Schering? The buzz about Schering-Plough on Wall Street is that the company is in play.
The Motley Fool July 24, 2007 Brian Lawler	Schering Doesn't Slow Schering-Plough continues its strong sales and earnings growth, but it has a big acquisition to digest in coming quarters.
The Motley Fool December 10, 2008 Brian Orelli	Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline.
The Motley Fool November 20, 2009 Brian Orelli	This Baby Is a Nice Addition A month into an acquisition, and Merck already sees a benefit.
The Motley Fool October 23, 2009 Brian Orelli	Merck-Schering Doesn't Look So Good Revenue is stagnant; let's hope that pipeline pans out.
The Motley Fool September 22, 2008 Brian Orelli	Let's Bail Out Pharma Next Schering-Plough is cutting jobs. Maybe the government should help out?
The Motley Fool January 9, 2009 Brian Orelli	Thanks for Nothing, FDA The Food and Drug Administration says there's still enough evidence that Merck and Schering-Plough's Vytorin works to warrant keeping patients on the drug.
The Motley Fool April 15, 2011 Brian Orelli	Dark Clouds Lift Over Pharma Dispute The case of who bought whom in the Merck -Schering-Plough deal has ended in a draw.
The Motley Fool April 21, 2005 Stephen D. Simpson	Schering-Plough Back in Black The turnaround seems to be working, as the company puts together consecutive quarters of good growth. But investors must realize that the company has a rather sparse late-stage pipeline relative to other large pharmaceutical peers.
The Motley Fool January 14, 2009 Brian Orelli	FDA's Bipolar Decision on Schering's Drug Signs point to an approval for Schering-Plough's schizophrenia and bipolar drug Saphris, but there isn't one yet.
The Motley Fool July 30, 2010 Brian Orelli	It's Hard to Get Excited About 92% Revenue Growth Especially when revenue dropped on a comparable basis.
BusinessWeek July 26, 2004 Amy Barrett	Hooked On The Cash From Cholesterol Cholesterol-lowering drugs are massive moneyspinners. But can big pharmaceutical companies sidestep expiring patents?
The Motley Fool April 22, 2008 Brian Orelli	Will Merck Make It? Merck releases first-quarter results and says it can meet its previous guidance.
The Motley Fool April 29, 2008 Brian Orelli	Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA.
The Motley Fool December 1, 2009 Robert Steyer	Merck Makes a Mark on Good Cholesterol Can't profit from fighting bad lipoproteins? Start boosting the good ones.
The Motley Fool November 30, 2006 Brian Lawler	Not Bad, Bayer The company's buyout of fellow German firm Schering AG looks like a boon to its bottom line. Investors, take note.
The Motley Fool November 27, 2007 Brian Orelli	Ploughing Into Acquisition Rewards Schering-Plough reaps its first New Drug Application from its purchase of Organon. Investors, take note.
The Motley Fool March 12, 2008 Brian Orelli	Will This Drug Help Schering-Plough Recover? FDA approval of Schering-Plough's muscle block medication Bridion looks certain, but will doctors see a need for it?
The Motley Fool April 2, 2008 Brian Lawler	Bad Timing for AstraZeneca's Good Data AstraZeneca quietly reports a successful clinical study for its cholesterol-lowering lead drug.
The Motley Fool June 25, 2010 Brian Orelli	Merck Breathes Life Into an Acquired Pipeline The acquisition is paying off with newly approved drugs.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.